Novel laser technology for biomedicine – Twenty-One Semiconductors successfully closes seed financing round with High-Tech Gründerfonds.

April 15, 2021

High-Tech Gründerfonds (HTGF) invests in the start-up Twenty-One Semiconductors (21S) as part of a first round of financing. The spin-off from the University of Stuttgart produces semiconductor-based laser crystals for biomedical applications. These crystals enable the realization of laser modules in the yellow spectral range, which is difficult to access with traditional laser technologies. Such yellow lasers are used to significantly increase the information content of biomedical investigations on cell- and tissue samples.

The demand for laser modules with central wavelengths in the visible spectral range is growing continuously due to an increasing variety of applications in biomedicine and life-science. In these fields, highly specialized laser sources are used to analyze blood and tissue samples in order to test the efficiency of new drugs and develop more effective therapies against cellular diseases.

Laser radiation is used to excite fluorescent dye molecules, which attach themselves to certain cell components with the help of receptors. The characteristic glow of the dye molecules provides information about the composition of the cell sample. By implementing laser modules with different wavelengths, i.e. colors, it is possible to excite a variety of different dyes and thus investigate a whole range of cell properties simultaneously. As a result, modern analyzers incorporate up to eight excitation lasers with different emission wavelengths.

Semiconductor diodes are typically used in red and blue laser modules. These have high efficiencies, are very compact and uncomplicated to handle. In the green and yellow spectral range, however, no efficient laser diodes are available. Thus most laser manufacturers rely on diode pumped solid-state lasers (DPSSL) there. In contrast to semiconductor diodes, these lasers are much more complex in their design and require the precise alignment of a large number of optical components as well as the exact temperature stabilization of the system. This makes them very expensive and complex to manufacture.

Over the past two years, based on extensive research at the Institute of Semiconductor Optics and Functional Interfaces at the University of Stuttgart, the founders of 21S have developed a novel laser crystal that can be used to generate visible laser radiation in a straightforward manner. This so called MEXL-crystal consists of a semiconductor membrane – 100 times thinner than a human hair – which is sandwiched between two transparent heat spreaders.

With the innovative MEXL concept (MEmbrane eXternal-cavity Laser) we enable laser manufacturers to build more efficient and compact laser modules in the green-yellow spectral range.

Dr. Roman Bek, founder and CTO of 21S

With the investment from HTGF, the young company plans to build up a portfolio of MEXL crystals and thus make the step from a development service provider to a manufacturing company.

With the MEXL, 21S has developed a novel design for technologically superior, optically pumped semiconductor laser modules. This enables fabrication of high-power lasers with virtually any output wavelength and superior beam characteristics at less complexity. Because these modules can be mass produced for the first time, the technology has enormous potential for a wide range of applications.

Dr. Gernot Berger, Investment Manager at HTGF

About Twenty-One Semiconductors (21S)
Twenty-One Semiconductors GmbH was founded in 2019 as a spin-off of the Institute of Semiconductor Optics and Functional Interfaces (IHFG) at the University of Stuttgart. The company produces and markets a completely new type of laser crystals that can be used to efficiently generate laser radiation in the visible spectral range.

The underlying MEXL technology enables laser manufacturers to realize a new generation of laser sources for biomedical applications to obtain even more detailed information when analyzing cell and tissue samples.

Twenty-One Semiconductors GmbH
Norbert Witz-Haszler, Managing Director
T.: +49711 – 685 – 63869

About High-Tech Gründerfonds
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 600 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and start-up experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected almost EUR 3 billion into the HTGF portfolio via more than 1,700 follow-on financing rounds. HTGF has also successfully sold interests in more than 120 companies.

Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Bank, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

Media Contact
High-Tech Gründerfonds Management GmbH
Stefanie Grüter, Head of Marketing & Communications
T.: +49228 – 82300 – 188

Investor Contact
Dr. Gernot Berger, Investment Manager
T.: +49228 – 82300 – 139

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

More News posts

23. May 2023

smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics

Munich, Germany, May 23, 2023 – smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the close of its seed financing round of €1.2 million from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF), bringing smartbax’s total capital raised to €1.9 million. The funds will be used to advance smartbax’s small molecule antibiotics through preclinical studies, expand the company’s scientific tea
15. May 2023

Using an app to combat skin conditions: Nia Health receives millions in funding

The Berlin-based health tech start-up Nia Health receives 3.5 million euros in a seed financing round. The company originates from the Charité Universitätsmedizin Berlin and operates leading dermatology apps, including "Nia," the most widely downloaded app for people with atopic dermatitis. The company has a network of renowned cooperation partners consisting of pharmaceutical companies, health insurance companies and clinics. The great potential lies above all in Nia Health's ex
Dualyx Logo
15. May 2023

Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its pipeline of Treg candidates Financing co-led by Fountain Healthcare Partners, Forbion and Andera Partners with support from existing investors Bernard Coulie appointed as Independent Chairman with immediate effect May 15, 2023, Ghent, Belgium – Dualyx NV, a Ghent based biotech developing next generation immune modulators, today announces that it has